^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

MIR424 (MicroRNA 424)

i
Other names: MIR424, MicroRNA 424, Hsa-MiR-424-3p, Hsa-MiR-424-5p, Hsa-Mir-424, MIR424, Hsa-Mir-15-P1d, MiRNA424, MIRN424, Mir-424, MIR322
12d
MiR-424-5p acts as an oncogene in Hep3B cells by activating the PI3K/AKT signaling pathway. (PubMed, Front Oncol)
These findings unveil an oncogenic role of miR-424-5p in HBV-HCC, suggesting its function is driven by viral specific dysregulation of the PI3K/AKT pathway, with PTEN involvement. Our study highlights miR-424-5p as a potential therapeutic target and provides insights into etiology-specific miRNA regulatory networks.
Journal
|
PTEN (Phosphatase and tensin homolog) • MIR424 (MicroRNA 424)
14d
Profiles of microRNAs in Patients with Advanced Breast Cancer Who are Chemoresistant or Chemosensitive to Fluorouracil, Adriamycin, and Cyclophosphamide Treatment. (PubMed, Asian Pac J Cancer Prev)
Therefore, these findings suggest that miRNAs may serve as predictive biomarkers and potential therapeutic targets in the management of breast cancer.
Journal
|
MIR152 (MicroRNA 152) • MIR27A (MicroRNA 27a) • MIR424 (MicroRNA 424) • MIR195 (MicroRNA 195) • MIR20A (MicroRNA 20a) • MIR214 (MicroRNA 214) • MIR222 (MicroRNA 222) • MIRLET7E (MicroRNA Let-7e)
|
5-fluorouracil • doxorubicin hydrochloride • cyclophosphamide
2ms
Identification of a Novel Salivary Four-miRNA Signature for Non-Invasive Diagnosis of Oral Squamous Cell Carcinoma. (PubMed, Int J Mol Sci)
A multivariate logistic regression combining miR-21, miR-31, miR-146a, and miR-424 yielded an AUC of 0.959, 96.7% specificity, and 86.7% sensitivity. Although limited by sample size, this study provides the first step for larger validation studies aimed at confirming the diagnostic utility of our salivary four-miRNA signature as a cost-effective and minimally invasive diagnostic tool for OSCC.
Journal
|
MIR21 (MicroRNA 21) • MIR31 (MicroRNA 31) • MIR424 (MicroRNA 424)
3ms
Progress of Exosomes in Cancer Immunotherapy. (PubMed, Cell Biochem Funct)
This review explores their multifaceted functions in cancer immunotherapy: in TME, tumor-derived exosomes (TDEs) drive immunosuppression, cancer-associated fibroblasts(CAFs) activation, and angiogenesis to promote progression and immune checkpoint inhibitors (ICIs) resistance; diagnostically, exosomal biomolecules (e.g., urinary miR-424/423/660/let-7i, serum LINC01125) serve as sensitive liquid biopsy markers for early detection and monitoring; therapeutically, engineered exosomes (e.g., DC-derived antigen-loaded ones) activate antitumor immunity and reverse ICIs resistance. These findings highlight exosomes' potential as diagnostic and therapeutic tools, laying a foundation for personalized cancer treatment.
Review • Journal • IO biomarker
|
MIR424 (MicroRNA 424)
3ms
Journal
|
MIR424 (MicroRNA 424)
4ms
Journal
|
MIR424 (MicroRNA 424)
5ms
Endometrial cancer progression driven by PTEN-deficiency requires miR-424(322)~503. (PubMed, Cell Death Dis)
Furthermore, the absence of miR-424(322)~503 restores TGFβ-induced apoptosis, which is otherwise compromised by PTEN deficiency. In vivo, Pten/miR-424(322)~503 knock-out mice exhibit reduced endometrial cancer progression compared to Pten deficient mice through a cell-autonomous mechanism.
Journal
|
PTEN (Phosphatase and tensin homolog) • TGFB1 (Transforming Growth Factor Beta 1) • MIR424 (MicroRNA 424)
5ms
Integrated miRNA-mRNA Analyses of Triple-Negative Breast Cancer in Black and White Patients with or Without Obesity. (PubMed, Int J Mol Sci)
Pathway enrichment analysis highlighted KRAS, ESR1, ESR2, RAB10, TNRC6C, and NCAN as the most commonly differentially expressed in EA, whereas ERBB4, PLCB1, and SERPINE1 were most frequently in AA. These findings highlight the importance of considering race-specific miRNA-mRNA signatures in understanding TNBC in the context of obesity, offering insights into biomarker-driven patient stratification for targeted therapeutic strategies.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • SERPINE1 (Serpin Family E Member 1) • MIR143 (MicroRNA 143) • MIR424 (MicroRNA 424) • CDC25B (Cell Division Cycle 25B) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • MIR130A (MicroRNA 130a) • MIR148A (MicroRNA 148a) • MIR181B1 (MicroRNA 181b-1) • MIR195 (MicroRNA 195) • MIR204 (MicroRNA 204) • MIR30A (MicroRNA 30a) • NCBP1 (Nuclear Cap Binding Protein Subunit 1) • RAB10 (RAB10, Member RAS Oncogene Family)
8ms
Prognostic value of LncRNA SH3BP5-AS1 in non-small cell lung cancer and its regulatory effect on tumor progression. (PubMed, Discov Oncol)
SH3BP5-AS1 is involved in NSCLC development by targeting its downstream target miRNA miR-424-5p, and it is a latent prognostic indicator for NSCLC.
Journal
|
MIR424 (MicroRNA 424) • SH3BP5-AS1 (SH3BP5 Antisense RNA 1)
9ms
Dauriporphine inhibited lung cancer cell viability, motility, and energy metabolism through the miR-424-5p/MAPK14 axis. (PubMed, Hereditas)
Dauriporphine inhibited cell growth, metastasis, and glycolysis-related energy metabolism of lung adenocarcinoma cells via modulating miR-424-5p/MAPK14 axis. Dauriporphine can be considered in drug development for lung adenocarcinoma.
Journal
|
MIR424 (MicroRNA 424) • MAPK14 (Mitogen-Activated Protein Kinase 14)